1. Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms
- Author
-
Lucia Conde, Leah Ensell, Javier Herrero, Martyn Caplin, John A. Hartley, Christos Toumpanakis, Clare Vesely, Nischalan Pillay, Alexa Childs, Christopher D. Steele, Francesca M Rizzo, Pawan Dhami, Christina Thirlwell, Helen Lowe, Tim Meyer, Heli Vaikkinen, and Tu Vinh Luong
- Subjects
Cancer Research ,DNA Copy Number Variations ,Endocrinology, Diabetes and Metabolism ,Evolutionary change ,Computational biology ,Neuroendocrine tumors ,Biology ,circulating tumor cells ,Endocrinology ,Circulating tumor cell ,Chromosome 18 ,medicine ,Biomarkers, Tumor ,Humans ,Copy-number variation ,Liquid biopsy ,Whole genome sequencing ,Whole Genome Sequencing ,Research ,copy number variation ,Cancer ,Genomics ,medicine.disease ,Neoplastic Cells, Circulating ,single cell ,Neuroendocrine Tumors ,Oncology ,whole-genome sequencing - Abstract
Single-cell profiling of circulating tumor cells (CTCs) as part of a minimally invasive liquid biopsy presents an opportunity to characterize and monitor tumor heterogeneity and evolution in individual patients. In this study, we aimed to compare single-cell copy number variation (CNV) data with tissue and define the degree of intra- and inter-patient genomic heterogeneity. We performed next-generation sequencing (NGS) whole-genome CNV analysis of 125 single CTCs derived from seven patients with neuroendocrine neoplasms (NEN) alongside matched white blood cells (WBC), formalin-fixed paraffin-embedded (FFPE), and fresh frozen (FF) samples. CTC CNV profiling demonstrated recurrent chromosomal alterations in previously reported NEN copy number hotspots, including the prognostically relevant loss of chromosome 18. Unsupervised hierarchical clustering revealed CTCs with distinct clonal lineages as well as significant intra- and inter-patient genomic heterogeneity, including subclonal alterations not detectable by bulk analysis and previously unreported in NEN. Notably, we also demonstrated the presence of genomically distinct CTCs according to the enrichment strategy utilized (EpCAM-dependent vs size-based). This work has significant implications for the identification of therapeutic targets, tracking of evolutionary change, and the implementation of CTC-biomarkers in cancer.
- Published
- 2021